Search Results
Your search for all items matches 34590 pages
Showing 251 - 300Botensilimab Plus Balstilimab in Relapsed or Refractory Metastatic Sarcomas
In a phase Ib study reported in the Journal of Clinical Oncology, Wilky et al found that the combination of botensilimab (Fc-enhanced anti–CTLA-4 antibody) and balstilimab (anti–PD-1 antibody) yielded activity in patients with relapsed or refractory metastatic sarcomas. Study Details In the trial,...
Discontinuation and Resumption of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
As reported in the Journal of Clinical Oncology by Mascarenhas et al, follow-up of a cohort of pediatric patients with TRK fusion sarcomas and related mesenchymal tumors treated with larotrectinib showed that discontinuation of treatment—with resumption for progressive disease—was associated with...
Results From FIRE-4 Show Liquid Biopsy Can Detect RAS/BRAF-Mutated Metastatic Colorectal Cancer
The results from the phase III FIRE-4 randomized clinical trial show that liquid biopsy accurately identified patients with RAS/BRAF V600E wild type–mutated metastatic colorectal cancer. The findings confirm the high clinical relevance of liquid biopsy performed at baseline before the start of...
AI May Boost Efficacy of Cancer Care, but Physicians Remain Critical to Decision-Making, Study Finds
Although artificial intelligence (AI)-assisted radiotherapy may help physicians make more informed decisions when treating patients with cancer, there may be challenges in how physicians work with the technology, according to a recent study published by Niraula et al in Nature Communications. Study ...
Neoadjuvant Radiotherapy May Hamper Immunotherapy Response in Patients With Breast Cancer
Researchers have provided novel insights into the effects of radiation on the immune cells surrounding breast cancer tumors, according to a recent study published by Yoneyama et al in the International Journal of Radiation Oncology • Biology • Physics. The findings revealed that the relationship...
Gastroenteropancreatic Neuroendocrine Tumor Incidence in the United States
In a study reported in a research letter in JAMA Oncology, Abboud et al found that the incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased in many organ sites during recent years in the United States. Study Details In the study, age-adjusted GEP-NETs incidence rates...
Adjuvant Chemotherapy After Preoperative mFOLFIRINOX and Resection of Localized Pancreatic Adenocarcinoma
In a retrospective cohort study reported in JAMA Oncology, Stoop et al found that use of adjuvant modified leucovorin, fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX) and other multiagent chemotherapy regimens improved overall survival vs no adjuvant chemotherapy in patients with localized...
Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL
A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), including those with isolated or combined extramedullary...
FDA Approves First Companion Diagnostic to Identify Patients With Metastatic Breast Cancer Eligible for T-DXd
The U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with hormone receptor (HR)-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with fam-trastuzumab...
Can R-CHOP–Like Therapy Effectively Treat Late-Relapse DLBCL?
Late relapse of diffuse large B-cell lymphoma (DLBCL) may represent a new lymphoma arising from a common precursor cell that is essentially chemotherapy-naive. Treatment with curative intent using a second-line regimen like R-CHOP (rituximab cyclophosphamide, doxorubicin, prednisone, and...
Predicting Response to KRAS G12C Inhibitors in NSCLC
Researchers may have uncovered a novel strategy to help predict how well patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) will respond to new therapies, according to a recent study published by Kato et al in Clinical Cancer Research. Study Methods and Results Researchers developed ...
Rising Advanced Prostate Cancer Rates in California Follow Changes to Recommendations
The incidence of advanced prostate cancer rose and the mortality rate plateaued in most regions across the state of California following the decision to cease routinely screening all men for the disease, according to a recent study published by Van Blarigan et al in JAMA Network Open. The findings...
Trastuzumab/Pertuzumab Plus Eribulin or Taxane in Locally Advanced or Metastatic Breast Cancer
In a Japanese noninferiority phase III trial (EMERALD) reported in the Journal of Clinical Oncology, Yamashita et al found that the addition of eribulin to trastuzumab/pertuzumab (HP) was noninferior in progression-free survival vs the addition of a taxane to HP in the first-line treatment of...
Thermal Ablation vs Surgical Resection of Small Resectable Colorectal Liver Metastases
In an interim analysis of a phase III noninferiority trial (COLLISION) reported in The Lancet Oncology, van der Lei et al found that thermal ablation was noninferior to surgical resection in terms of overall survival in patients with small resectable colorectal liver metastases. Study Details In...
Addition of Bevacizumab to Pembrolizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
In a Singaporean phase II trial reported in The Lancet Oncology, Chong et al found that the addition of bevacizumab to pembrolizumab improved objective response rate in patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma. Study Details In the open-label trial, 48...
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
Two pivotal phase III trials presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia (CLL), offering potentially more effective and tolerable treatment options for both...
Chemotherapy Linked to Chronic Neuropathy for 4 in Every 10 Patients: Global Analysis Results
Worldwide, cancer chemotherapy is linked to chronic painful neuropathy for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the available evidence published by D’Souza et al in Regional Anesthesia & Pain Medicine. Notwithstanding wide regional...
Cancer Symptoms Mistaken for Pregnancy Symptoms Could Lead to Delays in Cancer Diagnosis
Misdiagnosing cancer symptoms as normal pregnancy-related changes among pregnant individuals could lead to delays in treatment, according to a recent study published by Marcu et al in the British Journal of General Practice. Study Methods and Results In the study, researchers recruited 20 women...
Salpingectomy During Other Abdominal Surgeries May Lower Ovarian Cancer Risk
Fallopian tube removal performed during other abdominal surgeries could reduce the risk of ovarian cancer incidence among women who have already completed their families, according to a recent study published by Kather et al in PLOS Medicine. Background Ovarian cancer is the third most common...
Hereditary Ovarian Cancer Risk: Unlocking New Insights
Researchers have uncovered new heredity genes that may contribute to an increased risk of developing high-grade serous ovarian cancer, according to a recent study published by Subramanian et al in npj Genomic Medicine. Background High-grade serous ovarian cancer is one of the most prevalent and...
Does Brain MRI Surveillance Benefit Asymptomatic Patients With Stage IV Breast Cancer?
Researchers have found that asymptomatic brain metastases may be more common in patients with stage IV breast cancer than previously understood, according to a recent study published by Ahmed et al in Neuro-Oncology. The findings suggest that physicians may need to reconsider current screening...
TACE and Durvalumab/Bevacizumab in Unresectable HCC
In the phase III EMERALD-1 trial reported in The Lancet, Sangro et al found that transarterial chemoembolization (TACE) with durvalumab/bevacizumab improved progression-free survival vs placebo in patients with unresectable hepatocellular carcinoma (HCC) amenable to embolization. Study Details In...
CheckMate 7FL: Neoadjuvant Immunochemotherapy in ER-Positive, HER2-Negative Breast Cancer
A phase III trial has shown adding the PD-1 inhibitor nivolumab to anthracycline- and taxane-based chemotherapy that patients receive ahead of surgery may improve breast cancer cure rates. CheckMate-7FL involved 510 patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer,...
Tiragolumab Plus Atezolizumab/Bevacizumab in Unresectable, Locally Advanced, or Metastatic Hepatocellular Carcinoma
In a phase Ib-II study (MORPHEUS-Liver) reported in The Lancet Oncology, Finn et al found that the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab/bevacizumab improved objective response rate in patients with unresectable, locally advanced, or metastatic hepatocellular...
Expediting Cancer Diagnoses With Acoustofluidics?
A novel system using standing surface acoustic waves may effectively and precisely separate circulating tumor cells from red blood cells, according to a novel study published by Kouhkord and Naserifar in the Physics of Fluids. Background Cancer accounted for nearly 10 million deaths in 2020—nearly...
Talimogene Laherparepvec May Effectively Reduce Basal Cell Carcinoma Size Prior to Surgical Resection
Treatment with the oncolytic virus talimogene laherparepvec may be effective in patients with basal cell carcinoma, according to a novel study published by Ressler et al in Nature Cancer. Background Although basal cell carcinoma—which typically occurs in chronically sun-exposed areas such as the...
Fecal Microbiota Transplantation Following ASCT
Oral fecal microbiota transplantation may be a feasible and safe option to prevent graft-vs-host disease in patients with hematologic malignancies undergoing allogeneic stem cell transplant (ASCT), according to a recent report published by Reddi et al in Nature Communications. The findings built on ...
BOREAS Trial: Navtemadlin Demonstrates Clinical Benefit in JAK Inhibitor–Refractory Myelofibrosis
The oral MDM2 inhibitor navtemadlin is the first single agent to demonstrate significant efficacy in JAK (Janus kinase) inhibitor–refractory myelofibrosis, achieving improvements in spleen volume, symptoms, and biomarkers, according to data presented at the 2024 American Society of Hematology (ASH) ...
Perioperative Chemotherapy vs Preoperative Chemoradiotherapy in Resectable Locally Advanced Esophageal Carcinoma
In a German phase III trial (ESOPEC) reported in The New England Journal of Medicine, Hoeppner et al found that perioperative chemotherapy with fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) improved overall survival vs preoperative chemoradiotherapy in patients undergoing surgery for locally ...
Case 3: Steroid-Refractory Chronic GVHD With Sclerosis
This is Part 3 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the management of...
Case 2: Moderate Chronic GVHD
This is Part 2 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the management of moderate...
Case 1: Acute GVHD in a Patient With Lymphoma
This is Part 1 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the first-line treatment of...
Anna Martling, MD, PhD, on the ALASCCA Trial in Colorectal Cancer
The randomized, double-blind, multicenter, placebo-controlled ALASCCA Trial screened 3,508 patients across 33 hospitals in Sweden, Denmark, Finland, and Norway for eligibility. They either had stage II or III colon cancer or stage I, II, or III rectal cancer. Ultimately, 626 patients continued on...
FDA Highlights Importance of DPD Deficiency Discussions With Patients Prior to Capecitabine or Fluorouracil Treatment
The U.S. Food and Drug Administration (FDA) has provided a safety announcement to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil related to the risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Background Fluoropyrimidines are a...
Cathy Eng, MD, on the FRESCO-2 Study in Metastatic Colorectal Cancer
Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, reported on findings from the FRESCO-2 study, focusing on overall survival with fruquintinib vs placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer (Abstract 171). Abstract 171, a...
UICC‘s New World Cancer Day Campaign Calls for Fundamental Shift in Cancer Care Delivery
The Union for International Cancer Control (UICC) has introduced the new 2025 to 2027 United by Unique campaign, calling for a fundamental shift in cancer care and health systems across the world toward a people-centered approach in light of World Cancer Day. World Cancer Day takes place on...
Early-Stage Classic Hodgkin Lymphoma
“It isn’t the mountains ahead to climb that wear you out; it’s the pebble in your shoe.” —Muhammad Ali Long-term survival in early-stage classic Hodgkin lymphoma (cHL) was first made possible by the introduction of the mantle and inverted Y fields of radiotherapy in the 1960s. The addition of...
Young Patients With Cancer Living in Historic Redlined Neighborhoods Are Dying at Higher Rates Than Those in Nonredlined Areas
Studies have shown that adults living in historically redlined neighborhoods are less likely to be screened for breast, colorectal, and cervical cancers and have worse survival than those living in nonredlined areas. Redlining, a discriminatory, racist practice that began in the 1920s and 1930s in...
Neoadjuvant Nivolumab/Ipilimumab vs Chemotherapy in Resectable NSCLC
As reported in the Journal of Clinical Oncology by Awad et al, exploratory analysis of the comparison of neoadjuvant nivolumab/ipilimumab vs chemotherapy in the phase III CheckMate 816 trial found that nivolumab/ipilimumab was associated with numerically better event-free survival in patients with...
Addition of Cetuximab to Postoperative Radiotherapy in Intermediate-Risk Head and Neck Cancer
In a phase III trial (NRG/RTOG 0920) reported in Journal of Clinical Oncology, Machtay et al found that the addition of cetuximab to postoperative radiotherapy significantly improved disease-free survival—but not overall survival—in patients with completely resected, intermediate-risk, squamous...
Study Finds Therapeutic Vaccine Targeting HPV16 Is Safe and Effective in Eradicating Precancerous Cervical Lesions
The investigational therapeutic vaccine Vvax001 was found to be safe and showed preliminary clinical effectiveness in a phase II clinical trial of patients with HPV16-positive grade 3 cervical intraepithelial neoplasia. If confirmed in a phase III trial, the vaccine may provide a nonsurgical option ...
T-DXd Approved by the FDA for Pretreated Patients With HER2-Low or -Ultralow Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ...
Clearance of Driver Mutations after Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis
In a German single-center study reported in The New England Journal of Medicine, Gagelmann et al determined that clearance of driver mutations after allogeneic hematopoietic stem-cell transplantation was associated with better outcomes in patients with myelofibrosis. Study Details The study...
Pinpointing Contributing Factors in Response to Posttransplant Donor Lymphocyte Infusion in Patients With AML
Researchers have identified factors that could determine whether donor lymphocyte infusion—a type of adoptive cell therapy—will result in remission among patients with acute myeloid leukemia (AML) who have relapsed following allogeneic hematopoietic stem cell transplant (HSCT), according to a...
Anatomic Lung Resection May Be Linked to Improved Survival in Early-Stage NSCLC
Anatomic lung resections such as lobectomy and segmentectomy may be associated with improved long-term survival in patients with early-stage non–small cell lung cancer (NSCLC) compared with wedge resection, according to new findings presented at the 2025 Society of Thoracic Surgeons (STS) Annual...
Novel Combination Targeted Therapies, Chemotherapy in BRAF-Mutated Metastatic Colorectal Cancer
First-line treatment with the targeted therapies encorafenib and cetuximab plus a modified leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) chemotherapy regimen may be effective in patients with BRAF V600E–mutated metastatic colorectal cancer, according to recent findings presented by Kopetz et ...
Scott Kopetz, MD, PhD, FACP, on the BREAKWATER Study in BRAF V600–Mutant Metastatic Colorectal Cancer
The open-label, global, randomized phase III BREAKWATER study was an analysis of first-line encorafenib plus cetuximab plus chemotherapy in patients with BRAF V600E–mutant metastatic colorectal cancer. Here, Scott Kopetz, MD, PhD, FACP, of The University of Texas MD Anderson Cancer Center, reports ...
Melanoma Among Adult Survivors of Childhood Cancer
In a Childhood Cancer Survivor Study analysis reported in the Journal of Clinical Oncology, Rotz et al found that adult survivors of childhood cancers had a twofold increased risk of developing melanoma compared with the general population. Additionally, those with an invasive melanoma had a more...
New Findings on Aspirin and Risk of Colorectal Cancer Recurrence
According to one of the first biomarker-driven randomized study in people with nonmetastatic colorectal cancer, taking 160 mg of aspirin daily after treatment ends may reduce the risk of cancer recurrence in patients with cancers that harbor a PI3K mutation. These mutations are common to many types ...
New Research Explores Blood Test to Determine Prognosis, Benefit of Celecoxib in Stage III Colon Cancer
Previous research has shown that nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin and COX-2 inhibitors, may reduce the risk of developing colon cancer. A recent CALGB/SWOG study revealed that adding celecoxib to FOLFOX chemotherapy improved disease-free survival in patients with...
